U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H26N2O2
Molecular Weight 326.4326
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROQUININE

SMILES

[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2CC)[C@H](O)C3=CC=NC4=C3C=C(OC)C=C4

InChI

InChIKey=LJOQGZACKSYWCH-WZBLMQSHSA-N
InChI=1S/C20H26N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3/t13-,14-,19-,20+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/international/hydroquinine.html http://www.genome.jp/dbget-bin/www_bget?dr:D08265

Hydroquinine (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. It is available in the Netherlands since March 1990 as an over-the-counter drug with a dose of 200 mg with the evening meal and a further 100 mg at bedtime for 14 days. Hydroquinine also has antimalarial and demelanizing activity. It might be used to lightens light brown color patches on skin, age spots, skin discolorations associated with pregnancy, skin trauma or taking birth control pills. Hydroquinine is used in skin lightening creams and lotions because it is an effective bleaching agent, slowing the production of the tyrosinase enzyme and reducing the amount of melanin formed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
129.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Inhibin

Approved Use

Hydroquinine hydrobromide (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary.

Launch Date

1990
Curative
Unknown

Approved Use

Unknown
Primary
Hydroquinine

Approved Use

Hydroquinine is used for the treatment, control, prevention, and improvement of the following diseases, conditions and symptoms: Lightens light brown color patches on skin Age spots Skin discolorations associated with pregnancy Skin trauma Birth control pills Hormone replacement therapy during menopause
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

200 mg with the evening meal and a further 100 mg at bedtime for 14 days
Route of Administration: Oral
In Vitro Use Guide
The median inhibitory concentration (IC50) for hydroquinine against Plasmodium falciparum in vitro was 129 nmol/L (range 54-324)
Name Type Language
HYDROQUININE
MI   WHO-DD  
Common Name English
NSC-41799
Code English
QUININE HYDROCHLORIDE IMPURITY C [EP IMPURITY]
Common Name English
HYDROQUININE [MI]
Common Name English
DIHYDROQUININE [WHO-IP]
Common Name English
Hydroquinine [WHO-DD]
Common Name English
QUINIDINE SULFATE IMPURITY C [WHO-IP]
Common Name English
(-)-HYDROQUININE
Common Name English
DIHYDROQUININE
WHO-IP  
Common Name English
QUININE SULFATE IMPURITY C [EP IMPURITY]
Common Name English
10,11-DIHYDROQUININE
Common Name English
(R)-((2S,4S,5R)-5-ETHYL-1-AZABICYCLO(2.2.2)OCT-2-YL)(6-METHOXYQUINOLIN-4-YL)METHANOL [WHO-IP]
Systematic Name English
QUININE BISULFATE HEPTAHYDRATE IMPURITY C [WHO-IP]
Common Name English
CINCHONAN-9-OL, 10,11-DIHYDRO-6'-METHOXY-, (8.ALPHA.,9R)-
Common Name English
(8.ALPHA.,9R)-10,11-DIHYDRO-6'-METHOXYCINCHONAN-9-OL
Systematic Name English
QUININE BISULFATE IMPURITY C [WHO-IP]
Common Name English
(-)-10,11-DIHYDROQUININE
Common Name English
Classification Tree Code System Code
WHO-ATC M09AA01
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
WHO-VATC QM09AA01
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
Code System Code Type Description
FDA UNII
31J3Q51T6L
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
PUBCHEM
121515
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
CAS
522-66-7
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL2079611
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
MERCK INDEX
m6114
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB13718
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
WIKIPEDIA
DIHYDROQUININE
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
RXCUI
2468435
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
DRUG CENTRAL
4570
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-334-0
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
EVMPD
SUB14138MIG
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID70878516
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
SMS_ID
100000077600
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
NSC
41799
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY
DAILYMED
31J3Q51T6L
Created by admin on Fri Dec 15 20:38:47 GMT 2023 , Edited by admin on Fri Dec 15 20:38:47 GMT 2023
PRIMARY